Veracyte, Inc. Announces Study Published In JNCI Cancer Spectrum Demonstrates Real-World Utility Of Co's Decipher Prostate Genomic Classifier In Prostate Cancer Treatment
Portfolio Pulse from Happy Mohamed
Veracyte, Inc. (NASDAQ:VCYT) has published a study demonstrating the effectiveness of its Decipher Prostate Genomic Classifier in guiding personalized treatment for prostate cancer. The study used data from the National Cancer Institute's SEER database and showed that the Decipher test can accurately predict the likelihood of a patient's cancer metastasizing within the next five years. This information can help physicians recommend tailored treatment plans.
August 01, 2023 | 12:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The study reinforces the effectiveness of Veracyte's Decipher Prostate Genomic Classifier, which could potentially increase its adoption in the medical community and boost the company's revenues.
The study demonstrates the effectiveness of Veracyte's Decipher Prostate Genomic Classifier in predicting the likelihood of prostate cancer metastasizing. This could lead to increased adoption of the test by physicians, potentially leading to increased revenues for Veracyte.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100